Avanir Pharmaceuticals Inc Stock
Equities
US05348P4019
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff | RE |
2014 | NASDAQ OMX : names 14 stocks to test lower fee and rebate programme | RE |
Managers | Title | Age | Since |
---|---|---|---|
Dan Dalton
CMP | Compliance Officer | - | 16-05-31 |
Kelly Parker
IRO | Public Communications Contact | - | 15-05-31 |
Aneta Ferguson
LAW | General Counsel | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Hayden
CHM | Chairman | 68 | - |
Robert McQuade
BRD | Director/Board Member | 67 | - |
Thomas DesRosier
BRD | Director/Board Member | 69 | - |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- Stock